Guide for prioritisation of patients for referral to breast clinics

  • Research type

    Research Study

  • Full title

    Development of a decision support tool for ruling out cancer in patients referred from primary care for possible breast cancer diagnosis

  • IRAS ID

    266464

  • Contact name

    Nisha Sharma

  • Contact email

    nisha.sharma2@nhs.net

  • Sponsor organisation

    Leeds Teaching Hospitals Trust

  • Clinicaltrials.gov Identifier

    NCT 04474652

  • Duration of Study in the UK

    3 years, 0 months, 0 days

  • Research summary

    GPs in primary care in England currently refer over 2.17 million patients per year with vague symptoms to the urgent cancer referral pathway. While this catches over 150,000 cancer cases each year, 93% of the referred patients do not have cancer.

    For breast cancer, GPs refer 343,000 cases per year. Each of these patients are referred to a one stop clinic for diagnosis. The Leeds teaching Hospitals’ Trusts’ Breast Unit, receives 10,000 per year, with only 5% of patients actually being diagnosed with cancer.

    The breast cancer pathway involves a triple assessment process, which includes a clinical examination, imaging (mammogram or ultrasound) and possibly a biopsy test. It is a particularly expensive process as it is an imaging-intense pathway; this places considerable strain on NHS diagnostic facilities.

    Small changes will not be enough to solve this problem - a new approach is needed. The purpose of this study is to see if we can develop a blood test that can support doctors in identifying patients for whom the likelihood of having breast cancer is extremely low. This would avoid unnecessary referral for those patients to the one stop clinic. Patients with higher chances of suspected breast cancer would be referred to the one stop clinic in the usual way.

    Key to the idea of safely “ruling-out” patients is that the test must not miss patients who do have cancer. By measuring a broad range of indicators (markers) in blood, the test will provide a more accurate picture of the underlying biology. The test is also being developed within the NHS, so that it can be adopted quickly into NHS computer systems and laboratories to maximise patient benefit, whilst being held to the NHS’s high standards for clinical evidence and value.

  • REC name

    North of Scotland Research Ethics Committee 1

  • REC reference

    19/NS/0166

  • Date of REC Opinion

    8 Oct 2019

  • REC opinion

    Favourable Opinion